Positive headline results from the Vyepti (eptinezumab-jjmr) RELIEF study Aug 31, 2020 09:29AM
Survey Findings Highlight the Burden of Neurogenic Orthostatic Hypotension (nOH) on Patients and Care Partners Sep 24, 2018 11:00AM
TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD) May 2, 2018 05:36PM
Study Evaluates Refractory Epilepsy Screening Tool for LGS (REST-LGS) Dec 2, 2017 12:00PM
Lundbeck to Present Data on Movement Disorder and Epilepsy Therapies at AAN Annual Meeting Apr 18, 2017 10:00AM


Dec 2, 2016 09:00AM Citizens United for Research in Epilepsy (CURE) and Lundbeck Announce National Launch of Education Enrichment Fund
Oct 7, 2016 06:28PM FDA Approves Carnexiv™ (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
Sep 28, 2016 04:14PM Post-Hoc Analysis of Open-Label Extension Study Assesses the Use of ONFI® (Clobazam) CIV and the Potential for Tolerance
Apr 22, 2016 01:10PM FDA Accepts Lundbeck Resubmission of New Drug Application for Carnexiv™ (carbamazepine)
Apr 20, 2016 01:30PM New Initiative Sheds Light on an Often Undiagnosed Condition Associated with Parkinson’s Disease and other Nervous System Disorders
Apr 11, 2016 09:00AM Lundbeck to Present Data on Alzheimer’s, Epilepsy and Movement Disorder Medicines at AAN
Apr 7, 2016 09:00AM Patient Groups Rank Lundbeck US First in Corporate Reputation among Top Pharmaceutical Companies
Nov 25, 2015 09:30AM Largest Prospective Study Evaluating the Effect of Vigabatrin on Vision
Jun 15, 2015 03:30PM Analysis of Responder Data from Clinical Trials Evaluating NORTHERA® (droxidopa) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Apr 14, 2015 10:00AM Lundbeck and ‘Keep Memory Alive’ Invest to Support Multiple System Atrophy Research and Global Taskforce
Mar 17, 2015 10:00AM Lundbeck Initiates Clinical Trial Evaluating Clobazam for Dravet Syndrome